Immunovant Stock Surges 17% in 3 Months: What's Driving It?

Shares of Immunovant IMVT have surged 17% over the past three months, reflecting improving investor confidence, driven by encouraging pipeline progress and a strong financial position.

Immunovant’s Progress With IMVT-1402

The company continues advancing its lead next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor,IMVT-1402, across multiple autoimmune indications, including potentially registrational studies in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE).

Immunovant recently completed enrollment in the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA, with top-line data expected in the second half of 2026. Top-line data from potentially registrational clinical studies evaluating IMVT-1402 for the treatment of patients with GD and MG are anticipated in 2027. Immunovant expects top-line data from the CLE proof-of-concept study of IMVT-1402 in the second half of 2026.

Besides its lead candidate, Immunovant is also evaluating its second candidate, batoclimab, a fully human monoclonal antibody targeting FcRn, in ongoing mid-to-late-stage studies for two autoimmune indications, GD and thyroid eye disease (TED). The company expects to report top-line data from its two late-stage clinical studies for the treatment of patients with active, moderate-to-severe TED in the first half of 2026.

These clearly defined development milestones and upcoming catalysts have strengthened investor sentiment.

Over the past year, Immunovant shares have surged 40% compared with the industry’s 14.7% growth.

Strong Cash Position

The company’s financial position has improved significantly following a December 2025 underwritten financing that raised approximately $550 million from institutional investors, including Roivant Sciences.

As of Dec. 31, 2025, Immunovant’s cash and cash equivalents totaled $994.5 million, providing substantial liquidity to fund ongoing clinical programs and extending its cash runway through the potential commercial launch of IMVT-1402 for GD.

Immunovant, Inc. Price and Consensus

Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote

IMVT’s Zacks Rank & Stocks to Consider

Immunovant currently carries a Zacks Rank #3 (Hold).

Some top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals CPRX, which currently sports a Zacks Rank #1 (Strong Buy), Assertio Holdings ASRT and ANI Pharmaceuticals ANIP, both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.54 to $2.82. CPRX shares have gained 14% over the past year.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.08 to $8.22 for 2026. Over the past year, shares of ANIP have surged 25.3%.

ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.

Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have lost 0.6% over the past year.

Assertio’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, with the average negative surprise being 35.21%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research